BCM
AMRX icon

Bayesian Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Bayesian Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,754
Closed -$65.2K – 712
2024
Q1 		$65.2K Buy
+10,754
New +$60.6K 0.01% 730
2021
Q1 		– Sell
-14,184
Closed -$65K – 527
2020
Q4 		$65K Sell
14,184
-3,700
-21% -$16.4K 0.02% 423
2020
Q3 		$69K Buy
+17,884
New +$76.5K 0.02% 490

Other funds holding AMRX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayesian Capital Management's AMRX Position: Q2 2024 in Review

Bayesian Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2024, closing a stake of 10,754 shares — an estimated $65.2K sold.

Bayesian Capital Management first reported a position in AMRX in Q3 2020 and held it in 3 quarters. The position peaked at $69K in Q3 2020. 181 funds tracked by Wall St. Rank hold AMRX as of Q2 2024.

  • Bayesian Capital Management reported no remaining Amneal Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,754 Amneal Pharmaceuticals shares in Q2 2024, an estimated $65.2K.
  • Bayesian Capital Management first reported a position in Amneal Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • Bayesian Capital Management's Amneal Pharmaceuticals position peaked at $69K in Q3 2020.
  • 181 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2024.

Based on Bayesian Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.